Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CalbaTech, Inc.
Molecula receives license to key RNAi patent
January 14th, 2004
CalbaTech, Inc., (CLBE), which is focused on acquiring, incubating, and developing early stage life science companies and technologies, announced that Molecula, a Herndon, Virginia, subsidiary of CalbaTech, received a nonexclusive license to patent 6,506,599, "Genetic Inhibition by Double-Stranded RNA," from the Carnegie Institution of Washington, DC. Matt Maupin, Molecula CEO, stated, "Molecula is one of the leading companies in gene silencing technologies for gene and protein function studies. This is the most important patent in RNAi technology, and this license allows Molecula to aggressively compete in the RNAi market, which is expanding at an enormous rate. This...
Source: Biotech Week (2004-01-14)
|
